The lockup period of PolyPid Ltd. (PYPD) ends tomorrow, i.e., December 23.
PolyPid is a clinical-stage biopharmaceutical company developing prolonged-release therapeutics for surgical site infections using its proprietary PLEX technology.
The company's lead product candidate D-PLEX100 is currently in a phase III trial for the prevention of surgical site infections (SSIs) in abdominal surgery, dubbed SHIELD I. The top-line results from this study are expected in the second half of 2021.
A second phase III trial of D-PLEX100 for the prevention of post-abdominal surgery incisional infections, dubbed SHIELD II, was initiated as recently as December 16.
As of September 30, 2020, the company had cash and cash equivalents, short-term deposits and long-term deposits in the amount of $71.8 million.
PolyPid made its debut on The Nasdaq Global Select Market on June 26, 2020, offering its shares at a price of $16 each and the 180 day lockup period expires on December 23.
PYPD opened the first day of trading on June 26 at $16.00 and closed at $19.00 that day. The stock has thus far hit a low of $8.64 and a high of $19.45.
PYPD closed Monday's trading at $10.69, down 0.93%
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.